Induction of BRCAness in Triple-Negative Breast Cancer by a CDK12/13 Inhibitor Improves Chemotherapy

被引：19
|
作者：
Hopkins, Jessica L. [1 ]
Zou, Lee [1 ,2 ]
机构：
[1] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Charlestown, MA 02129 USA
[2] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
来源：
CANCER CELL | 2019年 / 36卷 / 05期
关键词：
D O I：
10.1016/j.ccell.2019.10.012
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In this issue of Cancer Cell, Quereda and colleagues report that a newly developed specific inhibitor of CDK12/13, SR-4835, sensitizes triple-negative breast cancer cells to PARP inhibitors and DNA-damaging chemotherapeutics by reducing expression of the genes in the DNA damage response pathway.
引用
收藏
页码：461 / 463
页数：4
相关论文
共 50 条
  • [1] CDK12/13 INHIBITOR SR-4835 IS ACTIVE IN TRIPLE-NEGATIVE BREAST CANCER
    不详
    CANCER DISCOVERY, 2019, 9 (12) : 1644 - 1644
  • [2] Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer
    Quereda, Victor
    Bayle, Simon
    Vena, Francesca
    Frydman, Sylvia M.
    Monastyrskyi, Andrii
    Roush, William R.
    Duckett, Derek R.
    CANCER CELL, 2019, 36 (05) : 545 - +
  • [3] Cooperative regulation of coupled oncoprotein synthesis and stability in triple-negative breast cancer by EGFR and CDK12/13
    Ang, Hazel X.
    Sutiman, Natalia
    Deng, Xinyue L.
    Liu, Annie
    Cerda-Smith, Christian G.
    Hutchinson, Haley M.
    Kim, Holly
    Bartelt, Luke C.
    Chen, Qiang
    Barrera, Alejandro
    Lin, Jiaxing
    Sheng, Zhecheng
    McDowell, Ian C.
    Reddy, Timothy E.
    Nicchitta, Christopher V.
    Wood, Kris C.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2023, 120 (38)
  • [4] BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
    Tanino, Hirokazu
    Kosaka, Yoshimasa
    Nishimiya, Hiroshi
    Tanaka, Youko
    Minatani, Naoko
    Kikuchi, Mariko
    Shida, Akiko
    Waraya, Mina
    Katoh, Hiroshi
    Enomoto, Takumo
    Sengoku, Norihiko
    Kajita, Sabine
    Hoffman, Robert M.
    Watanabe, Masahiko
    PLOS ONE, 2016, 11 (12):
  • [5] BRCAness and prognosis in triple-negative breast cancer patients treated with neoadjuvant chemotherapy
    Tanino, Hirokazu
    Kosaka, Yoshimasa
    Sengoku, Norihiko
    Waraya, Mina
    Nishimiya, Hiroshi
    Katoh, Hirozhi
    Kikuchi, Mariko
    Minatani, Naoko
    Teraoka, Saeko
    Enomoto, Takumo
    Sato, Takeo
    Masahiko, Masahiko
    CANCER RESEARCH, 2015, 75
  • [6] Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy
    Oonk, A. M. M.
    van Rijn, C.
    Smits, M. M.
    Mulder, L.
    Laddach, N.
    Savola, S. P.
    Wesseling, J.
    Rodenhuis, S.
    Imholz, A. L. T.
    Lips, E. H.
    ANNALS OF ONCOLOGY, 2012, 23 (09) : 2301 - 2305
  • [7] BRCAness and prognosis of triple-negative breast cancer patients treated with neoadjuvant chemotherapy.
    Akashi-Tanaka, Sadako
    Tanino, Yuichi
    Yamamoto, Yutaka
    Nishimiya, Hiroshi
    Yamamoto-ibusuki, Mutsuko
    Iwase, Hirotaka
    Nakamura, Seigo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] BRCAness Phenotype and Immune Microenvironment in Triple-Negative Breast Cancer
    Ramos Navas, Luisa Ayelen
    Esquivel Vazquez, Beatriz
    Salido Ruiz, Eduardo
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2024, 32 : 932 - 933
  • [9] Neoadjuvant Chemotherapy With Anthracycline-Based Regimen for BRCAness Tumors in Triple-Negative Breast Cancer
    Teraoka, Saeko
    Sato, Eiichi
    Narui, Kazutaka
    Yamada, Akimitsu
    Fujita, Tomoyuki
    Yamada, Kimito
    Oba, Mari
    Ishikawa, Takashi
    JOURNAL OF SURGICAL RESEARCH, 2020, 250 : 143 - 147
  • [10] Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer
    Zhang, Lan
    Zhen, Yongqi
    Feng, Lu
    Li, Zhijia
    Lu, Yingying
    Wang, Guan
    Ouyang, Liang
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 259
12345